Nova Patents
EP0403301A2

Aerosols of pyrido[1,2-a]pyrimidine compounds.

Abstract

A suspension type aerosol inhalations containing (a) 0.015 to 5.00 % (w/w) of a pyrido[1,2-a]pyrimidine compound of the formula: where R is a n-propyl or allyl group, A is a tetrazolyl or carboxyl group, and n is a whole number from 0 to 2, and (b) 0.015 to 5.00 % (w/w) of a fatty acid ester.

EP0403301A2, drawing sheet 1
Sheet 1 of 4

Term

Term ended

Projected expiry passed 15 June 2010, 16.3 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

10 claims: 6 independent, 4 dependent

  1. 1
    An aerosol composition containing (a) 0.015 to 5.00 % (w/w) of a pyrido[1,2-a]pyrimidine compound of the formula:where R is a n-propyl or allyl group, A is a tetrazolyl or carboxyl group, and n is a whole number from 0 to 2, and (b) 0.015 to 5.00 % (w/w) of a fatty acid ester.
  2. 6
    An aerosol composition as claimed in any of claims 1 to 5 wherein the pyrido[1,2-a]pyrimidine compound is in the form of particles, the diameter of said particles being in the range of 0.01 to 10µm, with at least 50% of the particles having a diameter of 2 to 5µm.
  3. 7
    An aerosol composition as claimed in any of claims 1 to 6 further comprising any fluorine-containing lower hydrocarbon propellant or mixtures thereof as a propellant.
  4. 8
    An aerosol composition as claimed in any of claims 1 to 7 further comprising a density modifier and/or solidification inhibitor.
  5. 9
    A process for the preparation of an aerosol composition, said process comprising admixing a pyrido[1,2-a]pyrimidine compound as defined in claim 1 together with a fatty acid ester, a fluorine-containing lower hydrocarbon and, optionally, a density modifier and/or solidification inhibitor.
  6. 10
    The use of an aerosol composition as claimed in any of claims 1 to 8 for the manufacture of a therapeutic agent for the treatment of bronchial asthma and allergic rhinitis.
Independent claims6